# Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

> **NCT06328725** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ENCell** · enrollment: 88 (estimated)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** EN001

## Key facts

- **NCT ID:** NCT06328725
- **Lead sponsor:** ENCell
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2025-11
- **Final completion:** 2025-11
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328725, "Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06328725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*